FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308333640> ?p ?o ?g. }

• W4308333640 endingPage "2806" @default.
• W4308333640 startingPage "2806" @default.
• W4308333640 abstract "Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD in clinical practice. Methods: We retrospectively enrolled 88 HTG-NAFLD patients treated with PEM for 6 months for the analysis of routine blood and body composition testing. A PEM response was defined as a decrease in serum alanine aminotransferase (ALT) of >30% compared with pre-treatment level. The clinical features related to PEM responsiveness were statistically tested between responders and non-responders. Results: All 88 patients completed the 6 month drug regimen without any adverse effects. PEM treatment significantly decreased liver enzymes, triglycerides, and total cholesterol levels, without any detectable impact on body weight or body composition. Comparisons of baseline clinical features revealed female and greater aspartate aminotransferase (AST), ALT, and fat mass % levels to be significantly associated with a PEM response. The optimal cut-off values to predict responders as determined by receiver operating characteristic analysis were AST 45 U/L, ALT 60 U/L, and fat mass 37%. Conclusions: Female HTG-NAFLD patients with higher transaminase and fat mass % levels may be preferentially indicated for PEM treatment. Additional large-scale prospective studies are warranted to verify our results." @default.
• W4308333640 created "2022-11-11" @default.
• W4308333640 creator A5020257285 @default.
• W4308333640 creator A5028354716 @default.
• W4308333640 creator A5034780792 @default.
• W4308333640 creator A5040458359 @default.
• W4308333640 creator A5041201763 @default.
• W4308333640 creator A5041908000 @default.
• W4308333640 creator A5044665501 @default.
• W4308333640 creator A5046084036 @default.
• W4308333640 creator A5056480475 @default.
• W4308333640 creator A5056535523 @default.
• W4308333640 creator A5057910360 @default.
• W4308333640 creator A5082222815 @default.
• W4308333640 date "2022-11-04" @default.
• W4308333640 modified "2023-10-05" @default.
• W4308333640 title "Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD" @default.
• W4308333640 cites W1615613652 @default.
• W4308333640 cites W1970220859 @default.
• W4308333640 cites W1997865776 @default.
• W4308333640 cites W1998426979 @default.
• W4308333640 cites W2036406892 @default.
• W4308333640 cites W2040109162 @default.
• W4308333640 cites W2087089023 @default.
• W4308333640 cites W2088337379 @default.
• W4308333640 cites W2110875907 @default.
• W4308333640 cites W2492424475 @default.
• W4308333640 cites W2588037944 @default.
• W4308333640 cites W2618863496 @default.
• W4308333640 cites W2620805790 @default.
• W4308333640 cites W2734724639 @default.
• W4308333640 cites W2759997926 @default.
• W4308333640 cites W2810423511 @default.
• W4308333640 cites W2883588014 @default.
• W4308333640 cites W2938214171 @default.
• W4308333640 cites W3010649284 @default.
• W4308333640 cites W3087664331 @default.
• W4308333640 cites W3092011810 @default.
• W4308333640 cites W3092644965 @default.
• W4308333640 cites W3131743383 @default.
• W4308333640 cites W3159244062 @default.
• W4308333640 cites W3169556382 @default.
• W4308333640 cites W3186664775 @default.
• W4308333640 cites W3198111024 @default.
• W4308333640 cites W3201123873 @default.
• W4308333640 cites W4200079926 @default.
• W4308333640 cites W4200189487 @default.
• W4308333640 cites W4205883090 @default.
• W4308333640 cites W4285023126 @default.
• W4308333640 doi "https://doi.org/10.3390/biomedicines10112806" @default.
• W4308333640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36359326" @default.
• W4308333640 hasPublicationYear "2022" @default.
• W4308333640 type Work @default.
• W4308333640 citedByCount "2" @default.
• W4308333640 countsByYear W43083336402023 @default.
• W4308333640 crossrefType "journal-article" @default.
• W4308333640 hasAuthorship W4308333640A5020257285 @default.
• W4308333640 hasAuthorship W4308333640A5028354716 @default.
• W4308333640 hasAuthorship W4308333640A5034780792 @default.
• W4308333640 hasAuthorship W4308333640A5040458359 @default.
• W4308333640 hasAuthorship W4308333640A5041201763 @default.
• W4308333640 hasAuthorship W4308333640A5041908000 @default.
• W4308333640 hasAuthorship W4308333640A5044665501 @default.
• W4308333640 hasAuthorship W4308333640A5046084036 @default.
• W4308333640 hasAuthorship W4308333640A5056480475 @default.
• W4308333640 hasAuthorship W4308333640A5056535523 @default.
• W4308333640 hasAuthorship W4308333640A5057910360 @default.
• W4308333640 hasAuthorship W4308333640A5082222815 @default.
• W4308333640 hasBestOaLocation W43083336401 @default.
• W4308333640 hasConcept C126322002 @default.
• W4308333640 hasConcept C134018914 @default.
• W4308333640 hasConcept C160160445 @default.
• W4308333640 hasConcept C181199279 @default.
• W4308333640 hasConcept C188816634 @default.
• W4308333640 hasConcept C2776877979 @default.
• W4308333640 hasConcept C2776919658 @default.
• W4308333640 hasConcept C2778163477 @default.
• W4308333640 hasConcept C2778606649 @default.
• W4308333640 hasConcept C2778772119 @default.
• W4308333640 hasConcept C2778913445 @default.
• W4308333640 hasConcept C2779134260 @default.
• W4308333640 hasConcept C2779679107 @default.
• W4308333640 hasConcept C2992872382 @default.
• W4308333640 hasConcept C55493867 @default.
• W4308333640 hasConcept C71924100 @default.
• W4308333640 hasConcept C86803240 @default.
• W4308333640 hasConcept C90924648 @default.
• W4308333640 hasConceptScore W4308333640C126322002 @default.
• W4308333640 hasConceptScore W4308333640C134018914 @default.
• W4308333640 hasConceptScore W4308333640C160160445 @default.
• W4308333640 hasConceptScore W4308333640C181199279 @default.
• W4308333640 hasConceptScore W4308333640C188816634 @default.
• W4308333640 hasConceptScore W4308333640C2776877979 @default.
• W4308333640 hasConceptScore W4308333640C2776919658 @default.
• W4308333640 hasConceptScore W4308333640C2778163477 @default.
• W4308333640 hasConceptScore W4308333640C2778606649 @default.
• W4308333640 hasConceptScore W4308333640C2778772119 @default.
• W4308333640 hasConceptScore W4308333640C2778913445 @default.

• next